Novo Nordisk reported that its Wegovy weight-loss pill reached 200,000 weekly prescriptions in the U.S. by mid-April, marking the fastest uptake ever in the GLP-1 drug category. Despite this strong demand, the Danish drugmaker only slightly raised its financial guidance for the year and still expects declines in profit and sales. This highlights strong market interest in weight-loss treatments but also ongoing challenges for Novo Nordisk's overall financial performance. Investors will watch how the company balances growth from Wegovy with broader business pressures moving forward.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
